The ocular oncology laboratory is dedicated to research leading directly to better treatments for ocular tumors. The focus is on combined modality focal therapies. Experimental models are utilized to investigate tumor responses to periocular chemotherapy, external beam radiotherapy, and hyperthermia. The lab actively translates new findings to the clinic.
Directed by Dr. Zelia Correa, the lab focuses on the identification of genetic, epigenetic and genomic abnormalities that lead to poor patient outcome in uveal melanoma, retinoblastoma and other eye cancers, with the goal of developing more accurate prognostic biomarkers and targeted molecular therapies that will lead to improved survival.
Read more about the lab’s current research projects and highlights.
Meet the ocular oncology laboratory’s team of visionary scientists.
The ocular oncology group is comprised of a dedicated team of researchers whose goal is to improve patient survival and discover new cancer breakthroughs.
Zelia M. Correa, M.D., Ph.D.
Director of Ocular Oncology
Biomedical Research Building